Tocilizumab; A potential remedy against the ever-evolving threat of Coronavirus-2 (SARS-CoV-2)
Madam, Coronavirus-2 (SARS-CoV-2) is a novel positive single-strand RNA virus that is the causative agent of COVID-19, which originated in Wuhan, China, at the end of December 2019. Since the beginning of 2020, this virus has taken the world by storm, brought the globe to an absolute crawl for the...
Main Authors: | Ghulam Mustafa Ali Malik, Samar Faheem |
---|---|
Format: | Article |
Language: | English |
Published: |
Pakistan Medical Association
2023-07-01
|
Series: | Journal of the Pakistan Medical Association |
Online Access: | https://www.ojs.jpma.org.pk/index.php/public_html/article/view/8551 |
Similar Items
-
The polybasic insert, the RBD of the SARS-CoV-2 spike protein, and the feline coronavirus - evolved or yet to evolve
by: Budhraja, Anshul, et al.
Published: (2021) -
Compassionate use of tocilizumab in severe SARS-CoV2 pneumonia
by: Miguel Górgolas Hernández-Mora, et al.
Published: (2021-01-01) -
Use of the rheumatic drug tocilizumab for treatment of SARS-CoV-2 patients
by: Bogna Grygiel-Górniak, et al.
Published: (2021-08-01) -
The evolving immunity to SARS-CoV-2
by: Dong Chen
Published: (2022-04-01) -
Scientists’ pursuit for SARS-COV-2 coronavirus: strategies against pandemic
by: S. V. Komisarenko
Published: (2020-12-01)